UC Gardner Neuroscience Institute Physician Highlight – Matthew Garrett, MD, PhD


Matthew Garrett, MD, PhD, specializes in neurosurgical oncology, specializing in gliomas and metastases. Dr. Garrett now serves at the University of Cincinnati College of Medicine Department of Neurosurgery as an assistant professor—where 50 percent of his time will be spent researching and innovating new therapies and treatments to increase survival for people with malignant brain tumors.

  1. What made you choose to work at UC Health?
    The University of Cincinnati has long been a home to bold innovations e.g. rotavirus and polio vaccines. Many of the tools we use in neurosurgery have names that trace back to UC neurosurgeons. I mostly work on glioblastoma, a universally fatal brain tumor. I choose to come to UC Health because they have the cutting edge biotechnology resources I need to bring some of my treatment ideas to fruition.
  2. How will this new UCGNI building benefit your patients?
    The treatment for primary brain tumors is complicated requiring multiple different specialty physicians e.g. neurosurgeons, neuro-radiologists, oncologists and radiation oncologists. The UCGNI provides a place for these specialties to work together. It not only makes the process more convenient for patients but also allows us to consult and discuss cases more quickly and easily.
  3. What kind of clinical work are you working on?
    We primarily use MRI to determine the amount of tumor tissue in a given patient. However, this is not always accurate. Sometimes benign things can look like tumor tissue and often tumor tissue can evolve and become undetectable on MRI. I am devising a test using either blood or cerebrospinal fluid that can measure the amount of tumor tissue in a patient.
  4. How will this benefit our patients with neurological issues?
    Once I can accurately measure the amount of tumor tissue in a patient I can prevent the need for unnecessary surgery on things that look like growing tumor but are not. Further I can determine when our therapies and medications are working and decreasing the amount of tumor or conversely when therapies are not working and the therapy needs to be changed.

Visit uchealth.com/neuroscience for more information.

This entry was posted in Articles. Bookmark the permalink. Both comments and trackbacks are currently closed.

Click Here to learn about our most recent COVID-19 updates including vaccine information, visitor restrictions, testing, and more.